09 June 2023 – Stewart Sharpe joins TMC as Chief Commercial Officer, with responsibility for overseeing the company’s continued UK and international success, with a number of new strategic relationships developed in North America, Asia, EU and the Middle East, as well as in the UK. Stewart is an enthusiastic business leader with a successful track record leading pharma organisations, building teams and launching pharma brands worldwide. He brings extensive experience to the role, having previously been VP Global Commercial Lead at Syneos Health, where he led and developed client-focused, fully integrated solutions for every stage of product development and commercialisation.
Stewart’s appointment is another milestone development in TMC’s growth since it secured an £18m minority investment from private equity firm LDC last year. Seeking to capitalise on the positive market dynamics, TMC has already strengthened its leadership team with the appointment of biotech industry veteran Gordon Cameron as a Non-Executive Director (Oct-22) and also by increasing its headcount by >20% since LDC’s investment.
With its UK headquarters in Hampshire and subsidiaries in the EU and Japan, TMC works predominantly with clients in North America, EU and Asia, and is unique in providing comprehensive medicinal product development support, from pre-clinical to post-marketing, for human medicines and devices, including all strategic and hands-on activities. With over 23 years of experience, TMC specialises in product development for rare/orphan diseases and oncology. TMC’s mature and exceptionally experienced team on-the-ground provide regulatory, medical, clinical and pharmacovigilance needs around the world.
“Our strong growth over the last year, supported by LDC’s experience and network, has meant we’re well positioned to attract exceptional industry talent and I believe we’ve built the perfect platform to accelerate our international growth as a result.”
Julie Matthews, Chief Executive Officer, TMC